Broadly neutralizing antibodies targeting HIV: Progress and challenges

Clin Immunol. 2023 Dec:257:109809. doi: 10.1016/j.clim.2023.109809. Epub 2023 Oct 16.

Abstract

Anti-HIV broadly neutralizing antibodies (bNAbs) offer a novel approach to treating, preventing, or curing HIV. Pre-clinical models and clinical trials involving the passive transfer of bNAbs have demonstrated that they can control viremia and potentially serve as alternatives or complement antiretroviral therapy (ART). However, antibody decay, persistent latent reservoirs, and resistance impede bNAb treatment. This review discusses recent advancements and obstacles in applying bNAbs and proposes strategies to enhance their therapeutic potential. These strategies include multi-epitope targeting, antibody half-life extension, combining with current and newer antiretrovirals, and sustained antibody secretion.

Keywords: Genetic diversity; HIV; Passive immunotherapy; bNAbs.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Neutralizing / therapeutic use
  • Broadly Neutralizing Antibodies / therapeutic use
  • HIV Antibodies / therapeutic use
  • HIV Infections* / drug therapy
  • HIV-1*
  • Humans

Substances

  • Broadly Neutralizing Antibodies
  • Antibodies, Neutralizing
  • HIV Antibodies